A survey of US hepatologists signals pent-up demand exists for the paradigm-changing HCV treatment, but that not all patients will get the drug right away.
Although doctors still like sales reps, Capgemini and Quantia's researchers find their appeal is on the decline, while digital is on the rise. While age is a factor, it's the workplace that's shaping physician preferences.
Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.
The commericalization/development deal covers up to six anti-cancer assets, and gives OncoMed a 50/50 US partnership over the experimental monoclonal antibody demcizumab.
Fundamental flaws in our current business model must be fixed if our industry is to stay vital and competitive into the next decade.
Their letter to CMS voices disagreement with the decision to make textbooks and journals reportable under the Sunshine Act.
The drug failed to hit its Phase III targets.
Phase-IIIb study results indicate Lyxumia—which is approved abroad but not in the US—was "non-inferior" in terms of controlling blood sugar levels regardless of whether the shot was given before breakfast or later.
Click on the image above to see a gallery of images from the 2013 MM&M Awards dinner
Missed MM&M's recent Skill Sets Live event on Multi-Screen Marketing? We're now giving you a second chance to get up to speed! Click here to access this insightful e-book with all the key take-aways.